Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882

News SummaryMost relevantAll newsSector newsTweets 

GlaxoSmithKline plc : GSK to acquire five million shares in Response Genetics for US$1.10 per share in cash

share with twitter share with LinkedIn share with facebook
share via e-mail
09/13/2012 | 02:29pm CET

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.

Issued: Thursday 13 September 2012, London, UK

GlaxoSmithKline plc (LSE: GSK) today announces that it has acquired five million newly issued shares of Response Genetics Inc. (RGI) (NASDAQ: RGDX) common stock at a purchase price of US$1.10 per share in cash. As a result, GSK now owns approximately 15.2% of the expanded share capital of RGI.

This transaction builds on the relationship GSK and RGI have been building over the years in the diagnostics field of oncology and vaccines. RGI performs companion diagnostic tests and other related activities for GSK's immunotherapies and oncology pipeline candidates.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

GlaxoSmithKline Enquiries:

UK Media enquiries:

David Mawdsley

+44 (0) 20 8047 5502


Stephen Rea

+44 (0) 20 8047 5502


Sarah Spencer

+44 (0) 20 8047 5502


David Daley

+44 (0) 20 8047 5502


US Media enquiries:

Kevin Colgan

+1 919 483 2933

(North Carolina)

Melinda Stubbee

+1 919 483 2510

(North Carolina)

Sarah Alspach

+1 202 715 1048

(Washington, DC)

Jennifer Armstrong

+1 215 751 5664


Analyst/Investor enquiries:

Sally Ferguson

+44 (0) 20 8047 5543


Tom Curry

+ 1 215 751 5419


Gary Davies

+ 44 (0) 20 8047 5503


James Dodwell

+ 44 (0) 20 8047 2406


Jeff McLaughlin

+ 1 215 751 7002


Ziba Shamsi

+ 44 (0) 20 8047 3289


GlaxoSmithKline cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK' s operations are described under 'Risk factors' in the 'Financial review & risk' section in the company's Annual Report 2011 included as exhibit 15.2 to the company's Annual Report on Form 20-F for 2011.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
03/17 GLAXOSMITHKLINE : *berenberg raises glaxosmithkline price target to 1890 pence -..
03/16 GLAXOSMITHKLINE : Study Findings on Neisseria meningitidis Are Outlined in Repor..
03/15 GLAXOSMITHKLINE : Submits US Application To Expand Fluarix Indication
03/15 GLAXOSMITHKLINE : New Glaxo boss set for pounds sterling 8.7m pay deal
03/15 Improved margins and Advair hopes lift drugmaker Hikma
03/15 GLAXOSMITHKLINE : GSK's new female CEO to get 25 percent less after pay policy r..
03/14 GLAXOSMITHKLINE : to invest HUF 18 bln in vaccine plant
03/10 GLAXOSMITHKLINE : GSK April 28th Options Begin Trading
03/09 GLAXOSMITHKLINE : Findings from GlaxoSmithKline plc Broaden Understanding of Imm..
More news
Sector news : Pharmaceuticals - NEC
03/22 MYLAN : recalls 81,000 EpiPens outside U.S. after reports of failure
03/21DJSANOFI'S PRESCRIPTION FOR GROWTH : Drug Sales in the Middle Kingdom
03/20 FTSE rises to record close after Article 50 trigger date set
03/17DJPFIZER : Files 8K - Other Events
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03/21 AstraZeneca's Mistakes Mount
03/21 Biotechs under pressure after Trump (again) decries high drug prices
03/16 When It Rains, It Pours For Gilead
03/15 Glaxo submits U.S. marketing application for expanded use of Fluarix vaccine ..
03/15 BIOTECH FORUM DAILY DIGEST : Opko Health Gets A Big 'Shout Out', Spotlight On Ad..
Financials ( GBP)
Sales 2017 29 933 M
EBIT 2017 8 426 M
Net income 2017 4 157 M
Debt 2017 13 625 M
Yield 2017 4,76%
P/E ratio 2017 19,84
P/E ratio 2018 17,43
EV / Sales 2017 3,22x
EV / Sales 2018 3,08x
Capitalization 82 629 M
More Financials
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 17,5  GBP
Spread / Average Target 4,4%
Consensus details
EPS Revisions
More Estimates Revisions
Andrew Philip Witty Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Birgitte Volck Head-Research & Development
Moncef Slaoui Executive Director & Chairman-Global Vaccines
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON10.45%344 961
ROCHE HOLDING LTD.8.81%216 473
PFIZER INC.5.45%203 963
NOVARTIS AG2.09%195 883
MERCK & CO., INC.8.56%175 469
More Results